REGN
Regeneron Pharmaceuticals, Inc.746.36
-6.26-0.83%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A colors pipeline edges
Q&A largely reaffirmed prepared remarks on robust pipeline momentum, offering incremental color on differentiators without guidance shifts or walk-backs. George highlighted a 'supi-dupi' next-gen DUPIXENT with potential longevity edges, alliance-covered, and genetics-guided I&I expansions. In GA, systemic C5 combos target better safety versus intravitreal rivals, with prospective visual acuity data. Obesity's GLP/GIP-PCSK9 co-formulation in one injector positions for comorbid patients. Analysts probed melanoma bars and GA uptake; management stayed confident. No new numbers. Pipeline execution matters next.
Key Stats
Market Cap
79.10BP/E (TTM)
17.89Basic EPS (TTM)
41.72Dividend Yield
0%Recent Filings
10-K
FY2025 results
Regeneron delivered FY2025 revenues of $14.3B, up 1% y/y, with net income climbing to $4.5B or $41.48 diluted EPS amid EYLEA HD ramping to $1.6B U.S. sales while EYLEA plunged 42% y/y to $2.7B on biosimilar launches and competition. Dupixent drove Sanofi profits to $5.2B (29% of sales), fueling 29% y/y collaboration revenue growth, yet EYLEA family U.S. sales dropped 27% y/y as HD uptake offset legacy erosion. Q4 momentum shone in Libtayo's 19% y/y global growth to $1.5B annual; cash flow hit $5B on robust ops. Debt steady at $2.7B with $19B liquidity; $1.5B buybacks left. Biosimilars threaten EYLEA quarterly volumes.
8-K
Q4 revenues $3.9B, up 3%
Regeneron reported Q4 2025 revenues up 3% to $3.9B, full-year up 1% to $14.3B, driven by Sanofi collaboration profits from Dupixent's 34% sales surge to $4.9B while total EYLEA HD/EYLEA U.S. sales fell 28% to $1.1B amid competition. EYLEA HD gained FDA nods for RVO and monthly dosing; Libtayo approved for high-risk adjuvant CSCC. Pipeline advances abound. Guidance signals R&D ramp to $6.5B.
8-K
Q4 charges, pipeline update
Regeneron disclosed preliminary Q4 2025 results at the J.P. Morgan Healthcare Conference on January 12, 2026, flagging a $19 million pre-tax IPR&D charge that hits GAAP and non-GAAP diluted EPS by $0.14, plus a $60 million matching donation to Good Days' retinal fund booked in SG&A. Pipeline shines with EYLEA HD demand up 10% QoQ and key 2026 milestones like fianlimab melanoma data. Actuals pending finalization.
8-K
Q3 revenues up 1%, key approvals
Regeneron reported third-quarter 2025 revenues of $3.75 billion, up 1% from last year, fueled by a 28% surge in Sanofi collaboration profits from Dupixent's $4.86 billion global sales, while total EYLEA HD and EYLEA U.S. net sales fell 28% to $1.11 billion amid competition and patient shifts. FDA approvals for Libtayo in high-risk adjuvant CSCC and Evkeeza in young HoFH kids bolster the oncology and rare disease pipelines. Pipeline advances shine. Yet manufacturing snags at Catalent delayed EYLEA HD's pre-filled syringe approval.
10-Q
Q3 FY2025 results
Regeneron posted solid Q3 results with total revenues edging up 0.9% y/y to $3.75B, driven by a 27% y/y surge in Sanofi collaboration revenue to $1.62B from stronger Dupixent profits, while U.S. net product sales dipped 18% y/y to $1.59B amid EYLEA's 41% y/y decline to $681M due to biosimilar launches and patient affordability issues—yet EYLEA HD grew 10% y/y to $431M. Operating income fell 13% y/y to $1.03B as R&D expenses climbed 16% y/y to $1.48B on pipeline investments, but net income rose 9% y/y to $1.46B ($13.62 diluted EPS, up 18% y/y) thanks to $756M in other income from investments. Cash flow from operations hit $3.81B YTD, supporting $2.77B in share repurchases and $278K in dividends; quarter-end cash and marketable securities stood at $18.73B, with $2.71B in debt and $750M revolver availability. No material M&A or impairments noted. Biosimilar erosion on EYLEA poses ongoing pricing risks.
ABBV
AbbVie Inc.
223.67-3.78
AMGN
Amgen Inc.
326.74+1.43
BIIB
Biogen Inc.
171.50-4.24
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
MRNA
Moderna, Inc.
29.89-0.03
PFE
Pfizer, Inc.
25.53-0.90
RGBP
Regen Biopharma, Inc.
0.01-0.00
RGNX
REGENXBIO Inc.
14.11+0.28
XNCR
Xencor, Inc.
16.55-0.24